LYON, France, June 15, 2023 – POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases , today announces its participation in the Scientific Symposium and Family Conference organized by the United Leukodystrophy Foundation (ULF) on June 23 and 24 in Itasca, Illinois, in the United States.
Sophie Bozec, Senior Vice President, Pharmacology & Scientific Communication at Poxel will present Poxel’s progress and plans for PXL770 and for the platform of deuterated TZD molecules (d-TZD), using PXL065, its two candidates promising proprietary drugs focused on the treatment of adrenoleukodystrophy (ALD), a rare genetic disease in adults, and whose development is based on solid scientific rationale and a complete preclinical set.
To receive information from POXEL in real time, send a request to [email protected].